108PRYR1 expression in the myogenesis of normal and dystrophic muscles

• Sep 01, 2025
• Neuromuscular Disorders
• I Zogbi + 6 more +6

Cite

Listen

Save

611PPersonalized aerobic training in Duchenne muscular dystrophy (DMD): an exploratory study to evaluate safety, feasibility, and impact on fatigue and quality of life.

• Sep 01, 2025
• Neuromuscular Disorders
• A Branca + 6 more +6

Cite

Listen

Save

59PUncovering therapeutic leads for SELENON-related congenital myopathy: a large-scale drug screen using patient-derived primary myoblasts

• Sep 01, 2025
• Neuromuscular Disorders
• A Ho + 2 more +2

Cite

Listen

Save

420PMeasurable difference neutral vertical head/trunk control between children with neuromuscular disorders and typically developing children

• Sep 01, 2025
• Neuromuscular Disorders
• T Willis + 4 more +4

Cite

Listen

Save

12PBioengineered muscle-on-a-chip for the study of inclusion body myositis

• Sep 01, 2025
• Neuromuscular Disorders
• F Andújar-Sánchez + 16 more +16

Cite

Listen

Save

394PMyotonic dystrophy type 2 as a phenotypic mimicker of inclusion body myositis

• Sep 01, 2025
• Neuromuscular Disorders
• P Yun + 2 more +2

Cite

Listen

Save

136PAlpha-dystroglycan expression analysis in urine-derived cells from Fukuyama congenital muscular dystrophy patients for clinical trials

• Sep 01, 2025
• Neuromuscular Disorders
• A Takahashi + 7 more +7

Cite

Listen

Save

593PLongitudinal assessment of 4-year HFMSE changes in SMA II and III patients treated with nusinersen

• Sep 01, 2025
• Neuromuscular Disorders
• G Coratti + 18 more +18

Cite

Listen

Save

261PNon-invasive tissue oxygenation monitoring in Duchenne muscular dystrophy rat models

• Sep 01, 2025
• Neuromuscular Disorders
• M Egiian + 5 more +5

Cite

Listen

Save

449PCopy-number variant and mobile element insertion analysis of whole-exome sequencing data from patients with neuromuscular disorders

• Sep 01, 2025
• Neuromuscular Disorders
• T Turku + 8 more +8

Cite

Listen

Save